Drug Type Small molecule drug |
Synonyms Cipralisant maleate (USAN), Perceptin |
Target |
Mechanism H3 receptor antagonists(Histamine H3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H20N2 |
InChIKeyCVKJAXCQPFOAIN-VXGBXAGGSA-N |
CAS Registry213027-19-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03518 | Cipralisant | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 2 | US | - | |
Attention Deficit Disorder With Hyperactivity | Phase 2 | - | - | |
Attention Deficit Disorder With Hyperactivity | Phase 2 | - | - | |
Attention Deficit Disorder With Hyperactivity | Phase 2 | US | - | |
Cognition Disorders | Phase 2 | US | - | |
Cognition Disorders | Phase 2 | US | - | |
Cognition Disorders | Phase 2 | - | - | |
Sleep Wake Disorders | Phase 2 | US | - | |
Sleep Wake Disorders | Phase 2 | US | - | |
Cognition Disorders | Discovery | - | - |